“…Schmitges et al suggested that performing a NVB-sparing procedure seems to be oncologically safe, only if patients are properly selected. 28 On the contrary, Antebi et al reported that the BCR-free and trifecta rates significantly decreased from low-, then intermediate-, and lastly, to high-risk patients 54 months after a RRP. 21 Pierorazio et al reported that the BCR-free rate was 96.4, 90.3, and 78.7% in the low-, intermediate-, and high-risk groups, respectively, at a median follow-up period of 4.4, 4.8, and 7.1 years after RRP, respectively (P < 0.001).…”